Compare Sana Biotechnology Inc (SANA) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Zillow Group Inc Class A — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Zillow Group Inc Class A trades at $31.83 (market cap $7.54B). The key difference: Zillow Group Inc Class A is far larger — about 8.6× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| SANA | ZG | |
|---|---|---|
Market Cap | $873.84M | $7.54B |
Sector | Health | Media |
52-Week High | $5.92 | $86.76 |
52-Week Low | $2.68 | $29.14 |
Enterprise Value | $848.03M | $7.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zillow Group (ZG) trades at $31.80, down 5.67% over 24 hours, amid a bearish technical signal and negative news flow. The company reported revenue of $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years. However, a high P/E ratio of 131.36 suggests premium valuation, while recent earnings showed a mix of beats and misses. Multiple law firms have announced securities class action investigations related to an alleged anticompetitive agreement, contributing to investor uncertainty.
The outlook is clouded by legal risks and rich valuation, though analyst consensus remains positive with a $57.80 price target. Upside potential hinges on sustained revenue growth and margin expansion, but downside risks include litigation outcomes and competitive pressures. Investors should weigh the strong analyst buy rating against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
